Jakavi 20 — Ruxolitinib 20 mg (56 Tablets)
Jakavi (Ruxolitinib) is a highly effective antineoplastic drug that acts as a selective inhibitor of Janus kinases (JAK1 and JAK2). These enzymes play a key role in the processes of hematopoiesis and immune response. In several myeloproliferative diseases, hyperactivity of the JAK pathways leads to uncontrolled blood cell division and the development of severe complications. Jakavi specifically blocks these signaling pathways, contributing to a reduction in spleen size and significant relief of disease symptoms.
Manufacturer: Novartis. Jakavi is the world's first drug approved for the targeted therapy of myelofibrosis, providing a significant improvement in patient survival and quality of life.
Key Features:
- ✅ Splenomegaly Control: Proven efficacy in reducing an enlarged spleen.
- ✅ Symptom Improvement: Effectively eliminates night sweats, skin itching, bone pain, and chronic fatigue.
- ✅ Targeted Therapy: Acts directly on the pathogenetic mechanism of the disease (JAK-STAT pathway).
Jakavi is prescribed by hematologists for the treatment of the following conditions:
- 🔹 Myelofibrosis: Including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adult patients.
- 🔹 Polycythemia Vera: In patients who are resistant to or intolerant of hydroxyurea therapy.
- 🔹 Graft-Versus-Host Disease (GVHD): Treatment of acute or chronic forms of the disease in patients with an inadequate response to corticosteroids.
Sales Form: 1 pack contains 56 tablets of 20 mg.
⚠️ INSTRUCTIONS FOR USE:
- Dosage Regimen: The dosage is selected strictly individually by a physician based on platelet and hemoglobin levels. Usually, the drug is taken twice daily (every 12 hours).
- Method: Tablets should be swallowed whole with water. They can be taken with or without food.
- Monitoring: During treatment, it is necessary to regularly perform a complete blood count to monitor platelet and white blood cell levels.
- Discontinuation of Therapy: Do not abruptly stop taking the medication without consulting a doctor, as this may cause a relapse of symptoms.
- Storage: Store at a temperature not exceeding 30°C in a dry place.
- ⛔ Hypersensitivity: Allergy to ruxolitinib or any other components of the tablets.
- ⛔ Pregnancy and Planning: The drug is contraindicated for pregnant women. Women of childbearing age should use reliable methods of contraception.
- ⛔ Lactation: Breastfeeding must be completely discontinued during therapy.
- ⛔ Laboratory Tests: Severe thrombocytopenia or neutropenia (low blood cell counts) before starting treatment require caution or delay of therapy.
- ⛔ Infections: Presence of severe active infections until they are cured.
Most frequently observed side effects requiring medical monitoring:
- 🩸 Hematology: Anemia, thrombocytopenia (low platelet count), neutropenia.
- 🤒 Infections: Increased risk of urinary tract infections, herpes zoster (shingles), flu-like conditions.
- 🧪 Metabolism: Increased blood cholesterol levels, weight gain.
- 🧠 Neurology: Dizziness, frequent headaches.
- ⚠️ Important: If unexplained bleeding, bruising, sudden fever, or a painful skin rash occurs, contact a hematologist immediately.
Similar products
What Customers Say
No reviews yet
Your review can be the first!